|
Learn from Boehringer Ingelheim & Pfizer about New Direct to Consumer Initiatives at the Virtual Pharmaceutical and Medical Device Pricing and Payment Transformation Summit
|
- Virtual Online Video Event Live and Archived
- Covering Tariffs, Most Favored Nation, TrumpRX, Direct to Consumer, Direct to Employer, Role of CMS & CMMI: GENEROUS, GLOBE, GUARD & BALANCE Models, IRA Medicare Drug Price Negotiations, Price Reporting, FDA Regulation, Medicaid Rebates, Medicare Fair Price, 340B and PBMs
- Media Partners: Harvard Health Policy Review, Health Affairs and Inside Health Policy
- June 16-19, 2026
- www.pharmapricingsummit.com
PRESS RELEASE
Phone: 800-503-7414
Email: reginfo@hcconferences.com
Website: www.pharmapricingsummit.com |
|
EARLY BIRD REGISTRATION
|
|
Click here to register by April 10 for early bird registration discount.
|
|
|
FEATURING NEW BUSINESS MODELS TO MEET PATIENTS WHERE THEY ARE BY
|
Peter Brensilver, MPH, JD
Senior Vice President, Chief Global Commercial Compliance, and Risk Counsel, Pfizer, New York, NY |
David Dopf, JD
Executive Director & Executive Counsel, US Human Pharma Business Law, Boehringer Ingelheim, Ridgefield, CT |
Stefanie A. Doebler, JD
Partner and Co-Chair, Health Care Practice Group, Covington & Burling, LLP, Washington, DC
(Co-moderator) |
Sarah A. Franklin, JD
Partner and Vice-Chair, Life Sciences Investigations Practice, Covington & Burling, LLP; Former Attorney, US Federal Trade Commission, Washington, DC
(Co-moderator)
|
|
WASHINGTON DC USA -- HEALTHCARE UPDATE NEWS SERVICE™ -- APRIL 3, 2026: The Virtual Pharmaceutical and Medical Device Pricing and Payment Transformation Summit will take place on June 16-19, 2026 as a purely virtual online event broadcast live and will remain available in video archive for 9 months. The Summit will cover the following matter relevant to pharmaceutical and medical device companies: Tariffs, Most Favored Nation, TrumpRX, Direct to Consumer, Direct to Employer, Role of CMS & CMMI: GENEROUS, GLOBE, GUARD & BALANCE Models, IRA Medicare Drug Price Negotiations, Price Reporting, FDA Regulation, Medicaid Rebates, Medicare Fair Price, 340B and PBMs.
|
|
FEATURING ROUNDTABLE ON THE IMPLICATIONS OF ACTUAL AND THREATENED US PHARMA TARIFFS BY
|
Neena Shenai, JD
Partner, WilmerHale; Former Chief Legal Counsel and Head of Compliance for Global Trade, Medtronic; Former Trade Counsel, Ways and Means Committee, US House of Representatives, Washington, DC |
Mariana P. Socal, MD, PhD, MPP, MSc
Associate Professor, Bloomberg School of Public Health and Carey Business School, Johns Hopkins University; Co-author, "Comparative Approaches to Drug Pricing" and "Tariffs as a Hidden Tax: Price Pass-Through in Multi-Stage Supply Chains", Baltimore, MD
|
Arun Venkataraman, MA, JD
Partner, Covington; Former Assistant Secretary of Commerce, US and Foreign Commercial Service, International Trade Administration; Former Counselor to the Secretary, US Department of Commerce, Washington, DC |
Joshua M. Sharfstein, MD
Vice Dean, Johns Hopkins Bloomberg School of Public Health; Former Secretary, Maryland's Health Department; Former Principal Deputy Commissioner, US FDA, Baltimore, MD (Moderator)
|
|
TARIFF COMPLIANCE ISSUES FOR PHARMACEUTICALS AND MEDICAL DEVICE COMPANIES BY
|
Shani Harmon Alexander, MS, JD
Senior Trade Counsel, Gilead; Former Director, Legal Manufacturing, Organon, Washington, DC |
Galina Free, MSc
Head of Trade Compliance, Danaher; Former Global Tax and Customs, Cisco, Bellevue, WA
|
Roger McCrary, JD
Senior Trade Counsel, Becton Dickinson; Former Vice President of Global Compliance, Momentive; Former Global Trade Compliance Program Leader, Medtronic, Oakland, MI |
Neena Shenai, JD
Partner, WilmerHale; Former Chief Legal Counsel and Head of Compliance for Global Trade, Medtronic; Former Trade Counsel, Ways and Means Committee, US House of Representatives, Washington, DC (Moderator)
|
|
AN OVERVIEW OF US PHARMA & DEVICE MOST FAVORED NATIONS/INTERNATIONAL REFERENCE PRICING INITIATIVES BY
|
Lanhee Chen, PhD
Fellow, Hoover Institution, Stanford; Former Counselor, HHS; Author, "Alternatives to Government-Imposed Price Controls to Lower US Drug Prices", Stanford, CA |
Liz Fowler, PhD, JD
Scholar, Johns Hopkins Bloomberg School of Public Health; Former Director, CMS CMMI (Biden); Former Special Assistant to President Obama, Washington, DC |
James Robinson, PhD
Schaeffer Professor of Health Economics & Director, Berkeley Center for Health Technology, University of California, Berkeley; Author, "Most Favored Nation Pricing is an Idea whose Time has Come", Berkeley, CA
|
Ian Spatz, MPA, JD
Principal, Rock Creek Policy Group; Former Vice President, Public Policy, Merck, Author, "Most Favored Nation Drug Pricing: Aiming at Pharma's Achilles Heel", Washington, DC |
Kristi Martin, MA, MPH
Founder, Highway 136 Consulting; Former Chief of Staff for Medicare, CMS; Former Health Care VP, Arnold Ventures, Washington, DC (Moderator)
|
|
|
|
AGENDA AVAILABLE
|
Click here to view the Agenda
|
|
EARLY BIRD REGISTRATION
|
Click here to register by April 10 for early bird registration discount.
|
|
SPECIAL PHARMACEUTICAL COMPLIANCE FORUM (PCF) REGISTRATION DISCOUNT
|
Register by April 10 for Early Bird Discount.
PCF member companies click here to register.
|
|
EXHIBIT & SPONSORSHIP OPPORTUNITIES
|
Click here for promotional opportunities.
|
|
PRODUCED BY
|
|
|
MEDIA PARTNERS
|
|
|
TUITION SCHOLARSHIPS
|
The Pharma Pricing Summit offers partial and full Tuition Scholarships to qualifying representatives of government, consumer advocate organizations, academics, students, representatives of health services research organizations, and those in employment transition.
Click here for more information.
|
|
|
IMPLEMENTING THE CMS/CMMI BALANCE, GENEROUS, GLOBE AND GUARD MODELS BY
|
Cindy Cerneka, MBA
Managing Director, Helio Health Group; Former Manager Government Reporting and Commercial Rebates, Mallinckrodt Pharmaceuticals, Durham, NC |
Tracy Mumpower
Director Managed Services, Helio Health Group; Former Manager, Commercial Contract Administration, King Pharmaceuticals, Bristol, VA |
Joseph Skupen, CPA
Managing Director, Senior Advisor and Technical Leader, Helio Health Group; Former Director FMV Tiering Global Medical Affairs, Sanofi, Berwyn, PA |
Stephanie Trunk, JD, CPS
Partner and Life Sciences Industry Group Co-Leader, ArentFox Schiff; Former Legal Counsel, Catalyst Health Solutions, Washington, DC |
Chris Cobourn, MS
Managing Director and Government Programs (GP) Practice Lead, Helio Health Group, Placida, FL (Moderator)
|
|
AND AN ADVAMED, BIO, AND PhRMA UPDATE BY
|
John Delacourt, JD
Deputy General Counsel, Vice President Health, Regulatory & Commercial Operations, Biotechnology Innovation Organization; Former Chief Antitrust Counsel, Office of Policy Planning, FTC, Washington, DC |
Ida Nassar, JD
Vice President, Assistant General Counsel, Ethics & Compliance, AdvaMed; Former Senior Attorney, Office of Chief Counsel, Drug Enforcement Administration, Washington, DC |
Julie Ritchie Wagner, JD
Senior Assistant General Counsel & Head of Global Ethics, Compliance & Enforcement Legal Policy, PhRMA; Former Senior Counsel, Office of Counsel to the Inspector General, US Department of Health and Human Services, Washington, DC
|
|
FEATURED FACULTY
|
Heather Banuelos, JD
Counsel, King & Spalding LLP; Former FDA Counsel, Allergan; Former Associate Chief Counsel, US Food and Drug Administration, Washington, DC |
Brian A. Bohnenkamp, MHA, JD
Partner, FDA and Life Sciences, King & Spalding, Washington, DC |
Catherine Brandon, JD
Partner, Arnold & Porter; Senior Counsel, Office of the Assistant Secretary for Legislation, US Department of Health and Human Services, Washington, DC |
Marijo G. Bustos, MBA
Head of Government Pricing & Reimbursement, UCB; Former Director, Prometic BioProduction & BioTherapeutics & Fresenius-Kabi USA, Smyrna, GA |
John Coster, PhD, RPh
Former Director, Division of Pharmacy, & Senior Advisor, Medicare Drug Rebate & Negotiation Program, CMS, Fort Lauderdale, FL
|
Niels Christian Ersboll, Master at Laws
Partner and Global Co-Chair Antitrust, Arnold & Porter, Brussels, Belgium |
Jeffrey Handwerker, JD
Partner, Arnold & Porter; Lead Author, "HHS-OIG Guidance on Manufacturer DTC Platforms and Congressional Pushback", Washington, DC |
Erin Hertzog, JD, MPH
Partner, Manatt, Phelps & Phillips LLP; Former Attorney, Office of the General Counsel, CMS Division, US DHHS; Former Director, Health Law & Policy, Biotechnology Industry Organization, Washington, DC |
Mary Kohler, JD
Founder and Principal, Kohler Health Law, PC; Former Expert Counsel, Worldwide Compliance & Business Ethics, Amgen; Former Assistant General Counsel, GSK, Los Angeles, CA |
Rosemary Maxwell, JD
Counsel, Arnold & Porter; Coauthor, "Trump Administration Issues Executive Order to Lower Prescription Drug Costs", Washington, DC
|
Mark McClellan, MD, PhD
Director, Robert J Margolis Center for Health Policy, Medicine and Health Policy, Duke University; Former CMS Administrator and FDA Commissioner (GW Bush), Washington, DC |
Nicholas Minter, MPP
Acting Director, Seamless Care Models Group, CMS Innovation Center; Former Senior Budget Analyst, HHS; Former Program Examiner, OMB, Silver Springs, MD |
Mickey Morgan
Acting Director, Division of Pharmacy, Center for Medicaid & CHIP Services, Center for Medicare and Medicaid Services, Washington, DC |
William Newton
Associate Editor/Senior Writer, 340B Report; Senior Healthcare Reporter, GlobalData Healthcare, Washington, DC |
Sayeh Nikpay, MPH, PhD
Associate Professor, School of Public Health, University of Minnesota; Lead Author, "When Safety-Net Programs Compete: Medicaid, 340B, and the Battle Over Drug Discounts", Minneapolis, MN
|
Lindsay Pronley
Director Managed Services, Life Science Revenue Management, Government Pricing & Commercial Contacting, Helio Health Group, Milwaukee, WI |
Nikki Reeves, JD
Partner and Co-chair, Life Sciences and Healthcare Industry Group, King & Spalding, Washington, DC |
Avik S. A. Roy
Co-Founder & Chairman, The Foundation for Research on Equal Opportunity; Chief Strategy Officer, Strive; Former Advisor, Presidential Campaigns of Marco Rubio, Rick Perry, and Mitt Romney, Austin, TX |
Gillian M. Russell, JD
Counsel, FDA & Life Sciences Practice, King & Spalding; Former Consultant, Corporate Executive Board, Washington, DC |
Valinda Rutledge, MBA
Executive Vice President, Policy and Advocacy, America's Physician Groups; Former Group Director, Patient Care Model Group and BPCI Lead, CMS, Washington, DC
|
William Sarraille, JD
Select Counsel, Rare Access Action Project (RAAP); Facioscapulohumeral Muscular Dystrophy (FSHD) Society; and AIDS Drug Assistance Programs (ADAPs); Former Partner, Sidley Austin, Washington, DC |
John Shakow, JD
Pharmaceutical Government Price Reporting Expert; Partner, FDA & Life Sciences Practice, King & Spalding LLP, Washington, DC |
Nick Shipley
Founder, Cronus Consulting; Former EVP, Biotechnology Innovation Organization (BIO); Former VP, Pharmaceutical Researchers and Manufacturers Association (PhRMA); Former Legislative Director, US House of Representatives, Washington, DC
|
|
FOR E-MAIL ADDRESS CHANGE, ADD OR DELETE REQUESTS:
|
|
For changes or additions, please email your request to: listmgr@HealthcareUpdateNewsService.com.
For automatic removal of your e-mail address, please click the "SafeUnsubscribe" link located in the footer of this message below.
|
|
